Contract research news in brief
pharmafile | September 4, 2012 | News story | Research and Development |Â Â CRO, Charles River, WuXiÂ
Charles River Laboratories (CRL) has paid $17 million for Accugenix, a company which provides endotoxin detection and microbial identity testing to pharmaceutical, medical device and consumer care product manufacturers. CRL said the deal boosted its ability to provide rapid microbial and endotoxin detection products and services to the biopharma industry, and will be followed with additional product extensions and acquisitions in the coming years. The acquisition is expected to be neutral to earnings in 2012.
WuXi PharmaTech‘s toxicology facility in Suzhou, China, has been granted Good Laboratory Practice (GLP) accreditation by the State Food and Drug Administration (SFDA) after passing two inspections. The company said the certification – which comes after a similar award from the Belgian authorities earlier this year “is further acknowledgment that we offer our clients non-clinical laboratory studies that meet national and international GLP quality standards”.
USA-based contract research organisation Quintiles has acquired Expression Analysis, a specialist in providing genomics testing and analysis services. EA employs 77 staff and provides whole genome to focused-set gene expression and genotyping assays, as well as sequencing services, sequence enrichment technologies and bioinformatics support. Financial terms of the deal have not been disclosed.
Molecular Profiles has formed an alliance with Onyx Scientific to provide a broad range of outsourced services to biopharmaceutical companies from drug discovery through to early- and late-phase manufacturing. Onyx will contribute its expertise in active pharmaceutical ingredient (API) screening and production, with Molecular Profiles bringing formulation, analytical development and small-scale manufacturing to the table.
INC Research has promoted chief operating officer Jamie Macdonald to the post of chief executive, taking over the role from James Ogle who stays on as the CRO’s chairman. Macdonald has been with INC for a little over one year and joined the company when it acquired Kendle in a $232 million deal in July 2011.
Phil Taylor
Related Content
Crown Bioscience opens new US model development centre
Crown Bioscience, a US global contract research organisation (CRO) that is part of JSR Life …
From molecule to market and beyond: Uniphar announces extended global commercialization platform
22 October 2024 – Dublin, Ireland – Healthcare services business, Uniphar, has developed its full-service …
Drug development contracts: can lessons be learned from healthcare delivery?
There is a very good question to ask at the beginning of every project: “What …
